Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG (OCS) is a clinical-stage biopharmaceutical company pioneering novel treatments for sight-threatening eye diseases. This news hub provides investors and healthcare professionals with timely updates on OCS's therapeutic advancements in ophthalmology.
Access official press releases and curated analysis covering clinical trial developments, regulatory milestones, and strategic partnerships. Our repository includes updates on key pipeline assets like OCS-01 for diabetic macular edema and OCS-02 for dry eye disease, along with neuro-ophthalmology innovations.
Stay informed about critical events including Phase trial results, FDA communications, licensing agreements, and scientific conference presentations. All content is verified through primary sources to ensure accuracy in this complex regulatory landscape.
Bookmark this page for streamlined tracking of Oculis's progress in developing precision therapies for retinal disorders and ocular surface diseases. Check regularly for material updates that could impact understanding of the company's clinical and commercial potential.
Oculis (Nasdaq: OCS) priced an offering of 5,432,098 ordinary shares at $20.25 per share for aggregate gross proceeds of $110 million, and granted underwriters a 30-day option to buy up to 703,703 additional shares. The Offerings split into an underwritten offering of 4,691,358 shares and a registered direct offering of 740,740 shares, expected to close on or about November 3, 2025.
Of the shares, 2,635,801 are new issue from the company’s capital band and 3,500,000 are treasury shares; issuance will raise authorized registered shares to 57,169,475. Net proceeds are intended to accelerate development of Privosegtor for acute optic neuritis and NAION, and for working capital and general corporate purposes.
Oculis (NYSE:OCS) disclosed two notifications dated Oct 14, 2025 showing a director exercised vested stock options and then sold the resulting ordinary shares.
The filings indicate the transactions were executed under a 10b5-1 trading plan in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934. Attachments reference notifications for C. Ackermann covering the option exercise and subsequent share sale.
Oculis (Nasdaq: OCS) will highlight its late-stage ophthalmology pipeline at Eyecelerator and the AAO Annual Meeting in Orlando, Oct 16–20, 2025.
Key updates include: Privosegtor advancing into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy after a positive meeting with the FDA; OCS-01 (DIAMOND Phase 3) with expected topline readouts in Q2 2026; and the planned PREDICT-1 registrational trial of Licaminlimab using a genotype-based approach anticipated to start in Q4 2025. CEO Riad Sherif will present at Eyecelerator on Oct 16, 2025; Oculis will also participate in Innovate Retina, SAIVO and COPhy events and staff booth 1353 during AAO.
Oculis (OCS) announced a notification of a manager's transaction dated October 8, 2025. The disclosure states that restricted stock units (RSUs) previously granted to director Riad Sherif have vested and been settled in October 2025. The notice includes an attachment with the formal managers' transaction notification.
Oculis (Nasdaq: OCS) announced a positive meeting with the FDA and is launching the PIONEER program to advance Privosegtor into registrational trials for acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION).
The company plans three pivotal studies: PIONEER-1 (Q4 2025), PIONEER-2 (1H 2026), and PIONEER-3 (mid-2026). Primary endpoint: low-contrast visual acuity (LCVA) at 3 months, with dosing/enrollment mirroring the positive Phase 2 ACUITY trial. Oculis reported preliminary cash, cash equivalents and short-term investments of ~$182 million, with runway expected into 2H 2027. Full Q3 2025 results are planned for November 10, 2025.
Oculis (NASDAQ:OCS) has announced that a Person Discharging Managerial Responsibilities (PDMR) has executed trades in accordance with a pre-established Rule 10b5-1 trading plan. The transactions were conducted under the Securities Exchange Act of 1934 guidelines, demonstrating compliance with regulatory requirements for insider trading.
Oculis (NASDAQ: OCS) announced upcoming presentation of positive Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis at ECTRIMS 2025 Congress. The trial demonstrated clinically meaningful improvements in vision with 18 letters at 3 months, preservation of retinal structure, and a favorable safety profile.
The presentation, scheduled for September 24, 2025, will be delivered by Dr. Céline Louapre from Pitié-Salpêtrière Hospital. The study showed promising neuroprotective effects, including preservation of retinal ganglion cells and significant improvements in low contrast visual acuity, highlighting potential applications in multiple sclerosis relapses and other neuro-ophthalmic conditions.
Oculis (NASDAQ:OCS) has announced the vesting and settlement of Restricted Stock Units (RSUs) for several company directors. The notifications concern RSU settlements for directors Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner.
Oculis (Nasdaq: OCS) and EURETINA have announced Dr. Prithvi Ramtohul as the winner of the 2025 Ramin Tadayoni Award, which honors exceptional postgraduate scholars in retina research. The award, established in 2024, commemorates Professor Ramin Tadayoni, Oculis' former Chief Scientific Officer.
Dr. Ramtohul, an attending physician at Aix-Marseille University Hospital and Ph.D. candidate, is recognized for his contributions to retinal imaging and diseases, with 111 peer-reviewed publications. His research focuses on cellular mechanisms of amblyopia and retinal disease pathophysiology through multimodal imaging analysis.
Oculis (NASDAQ:OCS) announced the vesting and settlement of Restricted Stock Units (RSUs) for director Arshad Khanani. The RSUs were previously granted as part of the company's equity compensation program.
FAQ
What is the current stock price of Oculis Holding (OCS)?
What is the market cap of Oculis Holding (OCS)?
